Paper Details

  1. Home
  2. Paper Details

AKR1C3 Inhibitor KV-37 Exhibits Antineoplastic Effects and Potentiates Enzalutamide in Combination Therapy in Prostate Adenocarcinoma Cells.

Author: GuptaNehal, PenningTrevor M, SrivastavaSanjay K, TrippierPaul C, VermaKshitij, WangtrakluldeePhumvadee, ZangTianzhu

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

KV-37, a potent AKR1C3 inhibitor, reduces prostate cancer cell growth *in vitro* and *in vivo* and sensitizes CRPC cell lines to enzalutamide.
Paper Details　
Original Abstract of the Article :
Aldo-keto reductase 1C3 (AKR1C3), also known as type 5 17 β-hydroxysteroid dehydrogenase, is responsible for intratumoral androgen biosynthesis, contributing to the development of castration-resistant prostate cancer (CRPC) and eventual chemotherapeutic failure. Significant upregulation of AKR1...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1158/1535-7163.MCT-17-1023

データ提供：米国国立医学図書館（NLM）

Targeting AKR1C3: A New Frontier in Prostate Cancer Treatment

This research explores the role of aldo-keto reductase 1C3 (AKR1C3) in prostate cancer, particularly in the context of castration-resistant prostate cancer (CRPC). It's like mapping out a new strategy for conquering a challenging desert fortress. The study investigates the potential of a potent AKR1C3 inhibitor, KV-37, as a novel therapeutic agent for treating prostate cancer. The findings suggest that KV-37 exhibits significant antitumor activity and enhances the effectiveness of enzalutamide, a current standard treatment for CRPC.

New Hope for Prostate Cancer: Targeting AKR1C3

This research offers a promising new approach to treating prostate cancer, particularly CRPC. It's like discovering a hidden well of hope in the desert of cancer research. The study demonstrates the potential of targeting AKR1C3 with the inhibitor KV-37 as a strategy for effectively managing prostate cancer and combatting the emergence of drug resistance.

Navigating Prostate Cancer Treatment: A Guide to Personalized Care

The findings of this research highlight the importance of exploring new therapeutic targets and innovative treatment approaches for prostate cancer. It's like finding a new route through a treacherous desert, offering a path to greater success. The study emphasizes the need for personalized treatment plans and continued research to identify effective therapies for different types of prostate cancer.

Dr.Camel's Conclusion

This research sheds light on the potential of targeting AKR1C3 with the inhibitor KV-37 as a novel approach to treating prostate cancer. It's like finding a new weapon in the arsenal of medical science, offering a chance to conquer this challenging disease. The study provides valuable insights into the intricate mechanisms of prostate cancer and suggests a promising direction for future research and development of new therapies.

Date :
  1. Date Completed 2019-09-03
  2. Date Revised 2021-12-04
Further Info :

Pubmed ID

29891491

DOI: Digital Object Identifier

10.1158/1535-7163.MCT-17-1023

Related Literature

Article Analysis
・Effects of enzalutamide
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.